
Raltegravir + Optimized Background Therapy for Resistant HIV BENCHMRK 1 and 2



Raltegravir with Optimized Background Therapy for Resistant HIV BENCHMRK 1 and 2: Study Design

Study Design: BENCHMRK 1 and 2

- Background: Two identical randomized, double-blind, phase 3 trials conducted in different geographic areas to evaluate the efficacy of raltegravir plus an optimized background therapy in persons with HIV resistant to at least one drug in each of three antiretroviral classes.
- Inclusion Criteria (n = 699 combined)
 - Age ≥16 years
 - HIV RNA >1000 copies/mL on ART
 - Documented resistance to at least 1 drug in NRTI, NNRTI, and PI classes
- Treatment Arms
 - OBT + Placebo
 - OBT+ Raltegravir 400 mg BID






Source: Steigbigel R, et al. N Engl J Med. 2008;59:339-54.

Raltegravir with Optimized Background Therapy for Resistant HIV BENCHMRK 1 and 2: Results

Week 48: Virologic Response (Non-completion Counted as Failure)



Source: Steigbigel R, et al. N Engl J Med. 2008;59:339-54.



Raltegravir with Optimized Background Therapy for Resistant HIV BENCHMRK 1 and 2: Conclusions

Conclusions: "In HIV-infected patients with limited treatment options, raltegravir plus optimized background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks."


Source: Steigbigel R, et al. N Engl J Med. 2008;59:339-54.



Raltegravir with Optimized Background Therapy for Resistant HIV BENCHMRK 1 and 2: Results

Week 96: Virologic Response, by Baseline HIV RNA

Optimized Background Therapy + Raltegravir
Optimized Background Therapy




Source: Steigbigel RT, et al. Clin Infect Dis. 2010;50:605-12.



Raltegravir with Optimized Background Therapy for Resistant HIV BENCHMRK 1 and 2: Results

Week 156: Virologic Response (Non-completion Counted as Failure)



Source: Eron JJ, et al. Lancet Infect Dis. 2013;13:587-96.



Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.



